Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease

Authors

  • Anil Kachroo MD, PhD,

    Corresponding author
    1. MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    • MassGeneral Institute for Neurodegenerative Disease, MGH, 114 Street, Charlestown, MA 02129
    Search for more papers by this author
  • Michael A. Schwarzschild MD, PhD

    1. MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    Search for more papers by this author

Abstract

To investigate the putative interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influences on Parkinson's disease (PD), we determined whether deletion of the adenosine A2A receptor in knockout (KO) mice protects against dopaminergic neuron degeneration induced by a mutant human α-synuclein (hm2SYN) transgene containing both A53T and A30P. The A2A KO completely prevented loss of dopamine and dopaminergic neurons caused by the mutant α-synuclein transgene without altering levels of its expression. The adenosine A2A receptor appears required for neurotoxicity in a mutant α-synuclein model of PD. Together with prior studies the present findings indirectly support the neuroprotective potential of caffeine and more specific A2A antagonists. Ann Neurol 2012;71:278–282

Ancillary